These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2823236)

  • 1. [Binding of technetium 99m-labeled heparin and its low molecular weight fractions CY 216 and CY 222 to human endothelium in vitro].
    Psuja P
    Pol Tyg Lek; 1987 Jul; 42(30):903-6. PubMed ID: 2823236
    [No Abstract]   [Full Text] [Related]  

  • 2. [Kinetics of binding of I-125-labeled heparin and its low-molecular-weight fraction CY 222 to the endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1987; 18(1-2):35-41. PubMed ID: 2829494
    [No Abstract]   [Full Text] [Related]  

  • 3. [Effect of antithrombin III on the binding of heparin and its low molecular weight fraction CY 216 with endothelium in vitro].
    Psuja P
    Acta Haematol Pol; 1988; 19(3-4):143-9. PubMed ID: 2855291
    [No Abstract]   [Full Text] [Related]  

  • 4. Affinity of binding of radiolabeled (125I) heparin and low molecular weight heparin fraction CY 222 to endothelium in culture.
    Psuja P
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1987; 114(3):429-36. PubMed ID: 2444518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of heparin fractions to von Willebrand factor: effect of molecular weight and affinity for antithrombin III.
    Baruch D; Ajzenberg N; Denis C; Legendre P; Lormeau JC; Meyer D
    Thromb Haemost; 1994 Jan; 71(1):141-6. PubMed ID: 8165633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture.
    Bârzu T; Molho P; Tobelem G; Petitou M; Caen JP
    Nouv Rev Fr Hematol (1978); 1984; 26(4):243-7. PubMed ID: 6473094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A method of assay of the anti-factor Xa activity of CY 216].
    Lormeau JC; Hajjar R
    Pathol Biol (Paris); 1988 Apr; 36(4):335-7. PubMed ID: 2836782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells.
    Vannucchi S; Pasquali F; Porciatti F; Chiarugi V; Magnelli L; Bianchini P
    Thromb Res; 1988 Feb; 49(4):373-83. PubMed ID: 2837834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin.
    Young E; Wells P; Holloway S; Weitz J; Hirsh J
    Thromb Haemost; 1994 Mar; 71(3):300-4. PubMed ID: 8029793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of heparan sulfate and its fractions with endothelial cells in culture.
    Tiozzo R; Cingi MR; Croce MA
    Int J Tissue React; 1993; 15(4):163-8. PubMed ID: 8188456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview: from heparin to low molecular weight heparin: beyond anticoagulation.
    Mousa SA; Fareed J
    Curr Opin Investig Drugs; 2001 Aug; 2(8):1077-80. PubMed ID: 11892916
    [No Abstract]   [Full Text] [Related]  

  • 12. Binding of low molecular weight heparin (Tinzaparin sodium) to bovine endothelial cells in vitro.
    Larnkjaer A; Ostergaard PB; Flodgaard HJ
    Thromb Res; 1994 Jul; 75(2):185-94. PubMed ID: 7974392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Passage of commercial heparin and a low molecular weight fragment of heparin, CY 222, across the placenta of pregnant rabbits].
    Doutremepuich C; Fantauzzi B; Masse A; Refauvelet J; Bousquet F; Toulemonde F; Quilichini R
    Pathol Biol (Paris); 1985 Jun; 33(6):677-9. PubMed ID: 3900887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle cell proliferation.
    Herbert JM; Maffrand JP
    J Cell Physiol; 1989 Feb; 138(2):424-32. PubMed ID: 2918044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 99m Technetium labelled heparin: potential value as a tracer of heparin activity in pharmacokinetic and biodistribution studies.
    Perdrisot R; Barbu M; Bok B; Berthelot JL; Mazoyer B; Colas-Linhart N
    Biomed Pharmacother; 1984; 38(8):414-6. PubMed ID: 6543145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of a very low molecular weight heparin fragment (CY 222) compared to standard heparin in patients with deep venous thrombosis. A randomized study].
    Faivre R; Neuhart E; Kieffer Y; Bassand JP; Maurat JP
    J Mal Vasc; 1987; 12 Suppl B():145-6. PubMed ID: 2834488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells.
    Young E; Venner T; Ribau J; Shaughnessy S; Hirsh J; Podor TJ
    Thromb Res; 1999 Dec; 96(5):373-81. PubMed ID: 10605952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Release of endothelium-associated proteins into blood by injection of heparin in normal subjects and in patients with Type 1 diabetes.
    Myrup B; Yokoyama H; Kristiansen OP; Østergaard PB; Olivecrona T
    Diabet Med; 2004 Oct; 21(10):1135-40. PubMed ID: 15384962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation by heparin fragments of thrombolysis induced with human tissue-type plasminogen activator or human single-chain urokinase-type plasminogen activator.
    Stassen JM; Juhan-Vague I; Alessi MC; De Cock F; Collen D
    Thromb Haemost; 1987 Oct; 58(3):947-50. PubMed ID: 2829381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.